Tamer I. Khayal - Jan 18, 2023 Form 4 Insider Report for TransMedics Group, Inc. (TMDX)

Role
Chief Commercial Officer
Signature
By: /s/ Stephen Gordon, Attorney-in-Fact
Stock symbol
TMDX
Transactions as of
Jan 18, 2023
Transactions value $
-$337,352
Form type
4
Date filed
1/20/2023, 05:12 PM
Previous filing
Jan 17, 2023
Next filing
Jan 25, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TMDX Common Stock Options Exercise $20.8K +1.3K +100% $16.00* 2.6K Jan 18, 2023 Direct F1
transaction TMDX Common Stock Sale -$84.6K -1.3K -50% $65.11 1.3K Jan 18, 2023 Direct F1, F2
transaction TMDX Common Stock Options Exercise $88.9K +5.56K +427.54% $16.00* 6.86K Jan 20, 2023 Direct F1
transaction TMDX Common Stock Sale -$362K -5.56K -81.04% $65.21 1.3K Jan 20, 2023 Direct F1, F3
holding TMDX Common Stock 11.1K Jan 18, 2023 By the Tamer Ibrahim Ahmed Khayal Trust
holding TMDX Common Stock 24.8K Jan 18, 2023 By the Khayal Family 2021 Irrevocable Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TMDX Stock Option (Right to Buy) Options Exercise $0 -1.3K -2.39% $0.00 53K Jan 18, 2023 Common Stock 1.3K $16.00 Direct F1, F4
transaction TMDX Stock Option (Right to Buy) Options Exercise $0 -5.56K -10.49% $0.00 47.4K Jan 20, 2023 Common Stock 5.56K $16.00 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transactions were effected pursuant to a Rule 10b5-1 trading plan.
F2 The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $65.00 to $65.30, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $65.00 to $65.56, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4 The option vests in equal monthly installments over four years beginning on the date of grant, May 1, 2019.